MX2022005445A - Tratamientos contra el cáncer dirigidos a las células madre cancerosas. - Google Patents

Tratamientos contra el cáncer dirigidos a las células madre cancerosas.

Info

Publication number
MX2022005445A
MX2022005445A MX2022005445A MX2022005445A MX2022005445A MX 2022005445 A MX2022005445 A MX 2022005445A MX 2022005445 A MX2022005445 A MX 2022005445A MX 2022005445 A MX2022005445 A MX 2022005445A MX 2022005445 A MX2022005445 A MX 2022005445A
Authority
MX
Mexico
Prior art keywords
cancer
compounds
stem cells
kits
compositions
Prior art date
Application number
MX2022005445A
Other languages
English (en)
Inventor
Yushma Bhurruth-Alcor
Gregory Thomas Crimmins
Jesús Diaz Dennise Alexandra De
Caroline Mae Robb
Original Assignee
Remedy Plan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Plan Inc filed Critical Remedy Plan Inc
Publication of MX2022005445A publication Critical patent/MX2022005445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Se describen compuestos, métodos, composiciones, usos y kits que permiten tratar el cáncer. En algunas modalidades, los compuestos se usan para tratar enfermedades o trastornos. Los compuestos pueden tratar el cáncer dirigiéndose a las células madre cancerosas. En algunas modalidades, el cáncer es cáncer colorrectal, cáncer gástrico, tumor del estroma gastrointestinal, cáncer de ovario, cáncer de pulmón, cáncer de mama, cáncer de páncreas, cáncer de testículo, linfoma, cáncer de hígado, cáncer de endometrio, leucemia o mieloma múltiple. Se describen compuestos, métodos, composiciones, usos y kits que pueden usarse en la medicina regenerativa. Los compuestos que se utilizan en la descripción tienen la fórmula (0) y (I).
MX2022005445A 2019-11-06 2020-11-06 Tratamientos contra el cáncer dirigidos a las células madre cancerosas. MX2022005445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931531P 2019-11-06 2019-11-06
PCT/US2020/059329 WO2021092322A1 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Publications (1)

Publication Number Publication Date
MX2022005445A true MX2022005445A (es) 2022-08-10

Family

ID=73643356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005445A MX2022005445A (es) 2019-11-06 2020-11-06 Tratamientos contra el cáncer dirigidos a las células madre cancerosas.

Country Status (12)

Country Link
US (1) US20230023124A1 (es)
EP (1) EP4055008A1 (es)
JP (1) JP2022553865A (es)
KR (1) KR20220110744A (es)
CN (1) CN114929672A (es)
AU (1) AU2020378067A1 (es)
BR (1) BR112022008753A2 (es)
CA (1) CA3157315A1 (es)
CO (1) CO2022007910A2 (es)
IL (1) IL292718A (es)
MX (1) MX2022005445A (es)
WO (1) WO2021092322A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
WO2008016643A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
CA2872652A1 (en) 2012-05-07 2013-11-14 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2014169073A1 (en) 2013-04-09 2014-10-16 Massachusetts Institute Of Technology Drug delivery polymer and uses thereof
CN112312899A (zh) * 2018-05-04 2021-02-02 治疗方案股份有限公司 靶向癌症干细胞的癌症治疗

Also Published As

Publication number Publication date
JP2022553865A (ja) 2022-12-26
CN114929672A (zh) 2022-08-19
US20230023124A1 (en) 2023-01-26
BR112022008753A2 (pt) 2022-07-19
CO2022007910A2 (es) 2022-08-19
AU2020378067A1 (en) 2022-05-26
EP4055008A1 (en) 2022-09-14
KR20220110744A (ko) 2022-08-09
WO2021092322A1 (en) 2021-05-14
IL292718A (en) 2022-07-01
CA3157315A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2021003389A (es) Metodos para tratar el cancer.
TN2018000213A1 (en) Compounds useful as kinase inhibitors
WO2016161410A3 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
MX2022004513A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
PH12018502572A1 (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
EA201991622A1 (ru) Комплексная терапия для лечения рака
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
MA40075A (fr) Combinaisons pour traiter des cancers
PH12020551853A1 (en) Axl kinase inhibitors and use of the same
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
MX2021002805A (es) Terapias de combinacion.
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
WO2019023315A3 (en) RAC INHIBITORS
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2018009913A (es) Aglutinantes max como moduladores myc y sus usos.
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
MX2022005445A (es) Tratamientos contra el cáncer dirigidos a las células madre cancerosas.
CO2022016819A2 (es) Compuestos novedosos útiles como inhibidores de poli(adp-ribosa) polimerasa (parp)
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.